clobetasol propionate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
clobetasol propionate: clinical details
Prescribing considerations
- Confirm a steroid-responsive diagnosis and whether a less potent corticosteroid has been inadequate.
- Match the vehicle to the site and lesion: cream for moist or weeping surfaces, ointment for dry or scaly lesions, and scalp-specific products for hairy areas.
- Minimise systemic absorption by avoiding unnecessary treatment of extensive areas, damaged skin and occlusion.
- Check formulation-specific age restrictions; children have proportionally greater absorption and susceptibility to local and systemic effects.
- Consider cumulative exposure from other topical, inhaled, oral or injected corticosteroids.
Contraindications and cautions
- Hypersensitivity to clobetasol propionate or formulation excipients.
- Untreated bacterial, viral, fungal or parasitic infection; scalp infection for the scalp application.
- Rosacea, acne vulgaris, perioral dermatitis, non-inflamed pruritus and perianal or genital pruritus for cream, ointment or foam as specified by the relevant product information.
- Ulcerated lesions or burns for the foam; shampoo must not be applied to ulcerated wounds, eyelids or eyes.
- Cream, ointment and scalp application are contraindicated in dermatoses in children under 1 year; selected foam and shampoo products have additional paediatric restrictions.
Monitoring
- Review diagnosis and adherence if the condition deteriorates or fails to respond.
- Check for infection, contact allergy, atrophy, striae, telangiectasia and withdrawal-type rebound.
- Assess for HPA-axis suppression or Cushingoid effects when absorption risk is increased; consider growth effects in children.
- Investigate new blurred vision or other visual symptoms; prolonged potent topical corticosteroid exposure may warrant ophthalmic assessment in at-risk patients.
Clinical pharmacology
A very potent glucocorticoid receptor agonist with anti-inflammatory, antipruritic and vasoconstrictive activity. Cutaneous absorption varies with vehicle, skin-barrier integrity, treated surface area and occlusion; absorbed corticosteroid is principally metabolised hepatically.
Formulation and product differences
- Cream is suited to moist or weeping lesions; it contains paraffin and can increase fabric flammability.
- Ointment is greasier and suited to dry, lichenified or scaly lesions; it also contains paraffin.
- Scalp application is an alcohol-based leave-on liquid and is highly flammable during and immediately after application.
- Cutaneous foam is a pressurised, flammable scalp preparation that melts on warm skin.
- Shampoo is a rinse-off scalp-only product licensed for moderate scalp psoriasis in adults; thorough rinsing reduces the risk of hair-colour changes.
clobetasol propionate preparations and strengths
Cutaneous foam
Route: Cutaneous
Strengths: 500 micrograms/g
Shampoo
Route: Cutaneous
Strengths: 500 micrograms/g
clobetasol propionate interactions
Systemic interactions are uncommon but become more relevant when skin absorption is increased.
Ritonavir and other strong CYP3A4 inhibitors
They can reduce corticosteroid metabolism and increase systemic exposure, especially with extensive or prolonged topical use.
Itraconazole and other strong azole CYP3A4 inhibitors
They can increase systemic corticosteroid exposure by inhibiting metabolism.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.